NCT07011004

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Phase I Study of Cytokine Induced Memory-Like Natural Killer Cells Combined With Atezolizumb in Subjects With Relapsed or Refractory Acute Myelogenous Leukemia

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.

Conditions

• Acute Myeloid Leukemia Refractory
• Acute Myeloid Leukemia, in Relapse

Interventions

Type	Name	Description
BIOLOGICAL	Cytokine Induced Memory-Like Natural Killer Cells	Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.
BIOLOGICAL	Atezolizumb	Single dose of Atezolizumab IV over 60 minutes IV.
BIOLOGICAL	CIML-NK cell therapy	CIML-NK cell therapy as an intravenous (IV) infusion

Timeline

• Start date: 2025-05-30
• Primary completion: 2028-05-01
• Completion: 2028-05-01
• First posted: 2025-06-08
• Last updated: 2026-04-09

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study